Allied Market Research has published a report titled “Primary Biliary Cholangitis Therapeutics Market by Drug Type (Primary Drug and Secondary Drug), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023β2032.” According to the report, the global primary biliary cholangitis therapeutics market was valued at $0.68 billion in 2022 and is expected to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.
Download Sample Copy –
https://www.alliedmarketresearch.com/request-sample/109023
Prime Factors Driving Market Growth
The increasing awareness of primary biliary cholangitis in developing countries, growing demand for effective therapeutics, and advancements in research and development are fueling market growth. However, challenges such as the lack of early diagnosis and limited treatment options hinder progress. On the other hand, the adoption of key strategies by industry leaders and the rising number of clinical trials for new drugs present lucrative opportunities for market expansion.
Impact of COVID-19 on Market Growth
The COVID-19 pandemic disrupted the primary biliary cholangitis therapeutics market due to supply chain issues, lockdown measures, and workforce shortages in manufacturing. However, with the resumption of research and development activities and the increasing prevalence of the disease, the market is on the path to recovery.
Market Segmentation Highlights
Drug Type: Primary Drug Segment to Lead Growth
In 2022, the primary drug segment accounted for more than four-fifths of the market share and is expected to maintain its dominance throughout the forecast period. The segment is projected to grow at a CAGR of 7.3% due to the rising adoption of primary drugs for treating primary biliary cholangitis and ongoing research efforts to enhance drug efficacy.
For Purchase Inquiry –
https://www.alliedmarketresearch.com/purchase-enquiry/109023
Distribution Channel: Drug Stores and Retail Pharmacies Dominate
Drug stores and retail pharmacies generated nearly three-fifths of market revenue in 2022, as a large number of patients rely on these outlets for their medication needs. However, the online pharmacies segment is expected to experience the fastest growth, with a CAGR of 8.6% from 2023 to 2032. Factors such as convenience, increased e-commerce sales, discounts, and flexible payment options are driving the rise of online pharmacies.
Regional Insights
North America led the market in 2022, accounting for over two-fifths of total revenue. This dominance is attributed to a well-established healthcare infrastructure, the presence of key pharmaceutical players, and high healthcare spending. Meanwhile, the Asia-Pacific region is projected to witness the highest CAGR of 8.5% through 2032, driven by an increasing prevalence of primary biliary cholangitis, unmet medical needs, and a large patient population.
Key Market Players
- ABC Farmaceutici S.p.A.
- Alkem Laboratories Limited
- AMAGEN INDIA LIFE SCIENCES
- GENFIT
- Intercept Pharmaceuticals, Inc.
- Ipsen Pharma
- Leeford Healthcare Ltd
- Lupin
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited
These leading players are adopting strategies such as acquisitions, product launches, and research advancements to strengthen their market presence. The report provides an in-depth analysis of their business performance, operating segments, product portfolios, and strategic developments.
Speak to Analyst –
https://www.alliedmarketresearch.com/connect-to-analyst/A108539
ππΏπ²πΎππ²π»ππΉπ πππΈπ²π± π€ππ²πππΆπΌπ»π?
Q1. What is the estimated industry size of Primary Biliary Cholangitis Therapeutics?
Q2. Which is base year calculated in the Primary Biliary Cholangitis Therapeutics Market?
Q3. What would be forecast period in the market report?
Q4. What are the upcoming trends of Primary Biliary Cholangitis Therapeutics Market in the world?
Q5. What is the leading segment of Primary Biliary Cholangitis Therapeutics Market?
ππ―πΌππ π¨π –
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
